top of page

Rafarma Pharmaceuticals continues to develop projects on isotopes in Kazakhstan

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) negotiated with The Institute of Nuclear Physics of the Ministry of Energy of the Republic of Kazakhstan. The parties discussed the possibilities of investment and cooperation in the pharmacological preparations, substances, and devices containing active isotope production for theragnostic and nuclear medicine.


During the meeting, the main topic of interest was the production of 177Lu at the VVR-K reactor with further PSMA synthesis in the radiochemistry unit. Also, the reactor is suitable for the irradiation of 90Y microspheres. The development of the production of emitting isotopes missing on the market will create a good potential for the company's growth in the world nuclear medicine field.


Now the parties continue to discuss cooperation and evaluate production volumes.



ABOUT THE INSTITUTE OF NUCLEAR PHYSICS

The Institute of Nuclear Physics of the Republic of Kazakhstan was established in 1957 to conduct research in the field of nuclear and solid-state physics. The institute is the only center in Kazakhstan for fundamental and applied research and training in the nuclear industry.


For more information, please visit https://inp.kz/en


ABOUT RAFARMA PHARMACEUTICALS

Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging, and many other fields.


For more information, please visit https://www.noyarp.com




FORWARD-LOOKING STATEMENT:

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACTS:

RAFARMA PHARMACEUTICALS

(307) 429-2029


Source: Rafarma Pharmaceuticals, Inc.


Comments


bottom of page